{"organizations": [], "uuid": "0debe765516035649e8038b7a591b1b0b14a140d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180426.html", "section_title": "Archive News &amp; Video for Thursday, 26 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-krystal-biotech-announces-fda-clea/brief-krystal-biotech-announces-fda-clearance-of-ind-on-kb103-for-the-treatment-of-dystrophic-epidermolysis-bullosa-idUSFWN1S30X9", "country": "US", "domain_rank": 408, "title": "Krystal Biotech Announces FDA Clearance Of IND On KB103 For The Treatment Of Dystrophic Epidermolysis Bullosa", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.997, "site_type": "news", "published": "2018-04-26T20:25:00.000+03:00", "replies_count": 0, "uuid": "0debe765516035649e8038b7a591b1b0b14a140d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-krystal-biotech-announces-fda-clea/brief-krystal-biotech-announces-fda-clearance-of-ind-on-kb103-for-the-treatment-of-dystrophic-epidermolysis-bullosa-idUSFWN1S30X9", "ord_in_thread": 0, "title": "Krystal Biotech Announces FDA Clearance Of IND On KB103 For The Treatment Of Dystrophic Epidermolysis Bullosa", "locations": [], "entities": {"persons": [], "locations": [{"name": "stanford", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "krystal biotech inc", "sentiment": "negative"}, {"name": "krystal biotech announces fda", "sentiment": "negative"}, {"name": "treatment of dystrophic epidermolysis bullosa", "sentiment": "negative"}, {"name": "epidermolysis bullosa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - Krystal Biotech Inc:\n* KRYSTAL BIOTECH ANNOUNCES FDA CLEARANCE OF IND ON KB103 TO BEGIN ENROLLING PATIENTS FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA\n* KRYSTAL BIOTECH INC - PLANNED PHASE 1/2 CLINICAL STUDY OF KB103 IS A SINGLE SITE STUDY AT STANFORD UNIVERSITY EXPECTED TO START IN MAY 2018\n* KRYSTAL BIOTECH INC - INITIAL DATA FROM STUDY OF KB103 ARE EXPECTED TO BE RELEASED BY END OF 2018 Source text for Eikon:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-26T20:25:00.000+03:00", "crawled": "2018-04-27T16:35:42.063+03:00", "highlightTitle": ""}